Data Demonstrate Safety and Tolerability of Microbiome Metabolic Therapy (MMT™) Candidate KB195 and Potential for Effect on Nitrogen Metabolism, a Biomarker of Ammonia Production LEXINGTON, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) — Kaleido Biosciences, Inc....
– Confirmed objective responses achieved in five of 13 evaluable patients – – Primary endpoint met prior to completion of enrollment with four patients experiencing progression-free survival greater than 6 months – – Proof-of-concept trial sponsored by Samsung Medical...
Regulatory News: Celyad (Paris:CYAD) (Brussels:CYAD) (NASDAQ:CYAD) (Euronext Brussels and Paris, and Nasdaq:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced the successful administration of...
Leuven, Belgium, 4 September 2019 – 7.30 AM CET- Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, announces the completion of enrollment of patients in a...
Mark Terry of Biospace writes: Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories. Emerald Health Pharmaceuticals completed its first-in-human Phase I clinical trial of EHP-101 in multiple...
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) announced today the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308), evaluating the efficacy and safety of APL-2 for treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH). PRINCE...
Email
Text